Washington D.C. — Daniel Nigh, a prominent attorney based in the nation’s capital, has distinguished himself as much more than a legal scholar. Founding partner of Nigh Goldenberg Raso & Vaughn, Nigh brings an extensive portfolio that spans various high-stakes arenas, including pharmaceutical and medical device litigations, as well as cryptocurrency exchange bankruptcies and mass torts.
Nigh’s expertise has not gone unnoticed. His adept handling of complex litigation has precipitated his appointments to several leadership roles in mass tort lawsuits that influence both the legal landscape and public health. Most notably, he presently serves as the co-lead counsel in the high-profile valsartan multidistrict litigation, MDL 2875, centrally managed in New Jersey. Simultaneously, he is deeply involved in the Zantac MDL in Florida, contributing his expertise as chair of both the science and experts committee and the Plaintiffs Steering Committee.
Prior to these significant appointments, Nigh laid foundational work in pharmaceutical litigation, starting with the Benicar drug lawsuit, for which he co-filed the initial case and subsequently chaired the discovery committee. His efforts were instrumental in securing a $358 million global settlement, demonstrating his ability to effectuate substantial outcomes in high stakes environments.
Nigh’s legal acumen also extends into defective medical device litigation, playing pivotal roles in the DePuy ASR, Bair Hugger, and transvaginal mesh litigations, among others. His leadership helped drive negotiations that led to major settlements in the DePuy Attune and DePuy Pinnacle hip litigation cases, further cementing his repute as a skilled negotiator and litigator.
Educationally, Nigh is as accredited as he is experienced. He graduated magna cum laude from Stetson Law School located in Gulfport, Florida. He also holds a Bachelor of Science in psychology with minors in business administration and math from Florida Southern College in Lakeland.
Beyond the courtroom, Nigh is a sought-after speaker, having presented on topics related to his field in over 60 panels at attorney conferences nationwide. His engagements include presentations at Mass Torts Made Perfect, American Association for Justice, and other notable legal assemblies. Additionally, he has authored numerous articles that have contributed to the scholarly discourse on pharmaceutical litigation and medical device controversies.
Nigh’s accomplishments have earned him recognition among his peers and broader legal communities. His achievements are highlighted by accolades such as inclusion in “The National Trial Lawyers Top 100” in 2023, and previously, “Top 40 under 40” in 2017. He is also a recognized figure in Super Lawyers listings, a testament to his standing within the legal profession.
As a member of the Florida Bar Association and admitted to practice in both the U.S. District Court for the Middle and Northern Districts of Florida, Nigh’s professional affiliations underscore his comprehensive qualifications and industry respect.
In summary, Daniel Nigh’s career is a testament to his dedicated pursuit of justice and his unparalleled expertise in navigating some of the most challenging domains of law. His continued impact on landmark pharmaceutical and medical device litigations ensures his legacy not only within legal circles but also in the lives of those affected by the cases he champions.